ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Allele-specific expression in the brain links genetic risk and cortical thinning in psychiatric disorders.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Allele-specific expression (ASE), where genetic variants exert dynamic control over gene expression, is not well studied in major psychiatric disorders. Here, we used transcriptome analysis in postmortem brain to identify genes with ASE, quantify differences in ASE in Schizophrenia (SCZ), Bipolar Disorder (BD), and Major Depressive Disorder (MDD), and explore regional relationships between differential ASE (dASE) and cortical thickness. Genome-wide analysis of ASE was performed by comparing RNA-sequencing read ratios of parental alleles in subgenual anterior cingulate cortex (sgACC) from 185 individuals with SCZ, BD, MDD, or no psychiatric disorder. ASE was detected by read-back phasing using phASER. dASE between cases and controls was performed using ASEP, a mixed model that accounts for sample information and correlation among SNPs. Heritability enrichment was calculated using linkage disequilibrium score regression. The Allen human brain atlas was used to map regional expression of dASE genes, which were compared with regional neuroanatomical changes reported in psychiatric patients. Of all 11,234 genes considered, 27% showed ASE at FDR < 0.05. Partitioned heritability analysis showed that ASE SNPs accounted for 13-16% of the heritability of MDD, BD and SCZ (enrichment p < 0.001). ASE SNPs significantly (p < 0.001) overlapped with GWAS variants in SCZ (odds ratio (OR) = 3.15), BD (OR = 2) and MDD (OR = 1.52). At FDR < 0.05, 1871 genes showed dASE in one or more diagnostic groups. These genes were enriched for regions with neuropsychiatric copy number variants (CNVs) and for several brain-relevant functional categories, especially those related to synapses. Expression of genes with dASE was increased in brain regions previously reported to show cortical thinning in patients with psychiatric disorders. This is the first study to explore the role of ASE in 3 major adult psychiatric disorders. We show that ASE is widespread in sgACC, that ASE SNPs contribute disproportionately to psychiatric disease heritability, dASE genes cluster in genomic regions with known neuropsychiatric CNVs and are most highly expressed in brain regions reported to show cortical thinning in psychiatric patients. Taken together, these findings highlight the importance of ASE in psychiatric disease risk and suggest that dysregulation of gene expression contributes to thinning of the cerebral cortex associated with psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.